NEWER ANTIVIRAL DRUGS FOR THE MANAGEMENT OF HEPATITIS C INFECTION IN POST RENAL TRANSPLANT PATIENT
Dr. Sincy Mery Chacko*, Dr. Divya Gopinath, Dr. Abel Abraham Thomas, Dr. Miliya Merry Gladson, Dr. Hima S. Shekar
ABSTRACT
Introduction: Chronic infection with hepatitis C virus (HCV) has
been found to an important health problem worldwide. The
management of HCV was difficult in kidney transplant patient before
the introduction of DAA. The present study was carried out to find the
efficacy of the newer antiviral drugs in the management of hepatitis c
infection in post renal transplant patient. Methods: Retrospective study
and prospective study was carried out in 199 patients from 2009 to
2015. Relevant information was obtained from the Old Patient case
records and follow up. Results: Of the 9 cases 7 were male and 2 were
females, mean age was 38.2 +/- 11.4 yrs. Among them 6 were positive
for HCV pre transplantation. 8 patients were genotype 1 and remaining
one was genotype 111. The mean pretreatment HCV viral load was 7375753.78 +/-
4364095IU/ml. All patients continued their immunosuppression therapy according to course
of therapy and graft function. Intended duration of therapy for all patients was 24weeks.
During therapy 4week viral load was available and was undetectable in 7 patients. And at
12weeks all were undetectable. Out of 9 patients who were given with ribavirin 5 was found
to be anemic. Conclusions: The newer antivirals such as DAA shows higher safety and good
efficacy in patients who were contraindicated for interferon.
Keywords: Hepatitis C, Anti Viral, Ribavirin, Interferon, Viral Load, Direct-Acting Antivirals, Sobosfovir.
[Full Text Article]